Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An atypical meningioma which may recur in approximately 29-40% of the cases. This category includes the atypical meningioma, chordoid meningioma, and clear cell meningioma.
Biomarker and diagnostic research for grade II meningioma has been reported in the published literature.
8 clinical trials registered, 5 recruiting. Interventions under study include procedural interventions, drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 5 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04082520](https://clinicaltrials.gov/study/NCT04082520) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy |
PHASE2 |
Mayo Clinic |
RECRUITING |
[NCT04659811](https://clinicaltrials.gov/study/NCT04659811) | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | PHASE2 | Nancy Ann Oberheim Bush, MD | ACTIVE_NOT_RECRUITING |
[NCT02847559](https://clinicaltrials.gov/study/NCT02847559) | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | PHASE2 | Northwestern University | UNKNOWN |
[NCT04278118](https://clinicaltrials.gov/study/NCT04278118) | Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study | NA | Emory University | RECRUITING |
[NCT07428616](https://clinicaltrials.gov/study/NCT07428616) | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | PHASE2 | Exelixis | RECRUITING |
44 publications have been identified in PubMed for grade II meningioma. Research spans Case Report / Case Series (32%), Epidemiology / Natural History (18%), and Clinical Trial Publication (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 | 32% |
Disease patterns and progression | 8 | 18% |
Clinical study results | 7 | 16% |
Research summaries | 6 | 14% |
Testing and diagnosis research | 5 | 11% |
Laboratory research | 3 | 7% |
Other research | 1 | 2% |
Paterra R (2026). [PMID: 41792855](https://pubmed.ncbi.nlm.nih.gov/41792855/). *Acta Neuropathol Commun*. [Diagnostic / Biomarker]
Ito E (2026). [PMID: 42192905](https://pubmed.ncbi.nlm.nih.gov/42192905/). *Cancers (Basel)*. [Epidemiology / Natural History]
Ward K (2026). [PMID: 41716511](https://pubmed.ncbi.nlm.nih.gov/41716511/). *Can Vet J*. [Case Report / Case Series]
Ishag Isa S (2026). [PMID: 41568301](https://pubmed.ncbi.nlm.nih.gov/41568301/). *J Surg Case Rep*. [Case Report / Case Series]
Maier AD (2026). [PMID: 41486296](https://pubmed.ncbi.nlm.nih.gov/41486296/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Whipple-Bones S (2026). [PMID: 41568195](https://pubmed.ncbi.nlm.nih.gov/41568195/). *Neurosurg Focus Video*. [Other]
Ehret F (2026). [PMID: 42149137](https://pubmed.ncbi.nlm.nih.gov/42149137/). *Clin Cancer Res*. [Clinical Trial Publication]
Demircan V (2026). [PMID: 42086919](https://pubmed.ncbi.nlm.nih.gov/42086919/). *J Neurooncol*. [Epidemiology / Natural History]
De Los Reyes-Lara AO (2026). [PMID: 42005111](https://pubmed.ncbi.nlm.nih.gov/42005111/). *Cureus*. [Case Report / Case Series]
Pandey VK (2026). [PMID: 41804397](https://pubmed.ncbi.nlm.nih.gov/41804397/). *Cureus*. [Case Report / Case Series]